Takeda's innovation in Korea

Takeda has been in Korea for 10 years

Focus on patient-centered philosophy and innovative drug development

Share the achievements of the four major domestic business units and their strategies in the future

Moon Hee-seok, CEO of Takeda Korea

Takeda Korea, which sold off OTC division & DM division, which was the company's symbol.

 

On the occasion of the 10th anniversary of the corporation's launch, constraints have once again confirmed their commitment to pursuing innovation.

 

Marking the 240th anniversary of Takeda Pharmaceutical's headquarters and Korea Takeda's 10th Anniversary, 'Takeda has achieved innovative growth for patients,' it held an online press conference.

 

At this press conference, Take Korea is in line with four key treatment areas: anti-cancer, gastrointestinal disease, nervous system disease, and rare diseases.The general managers of the four major pharmaceutical businesses announced major portfolios and core strategies of each business unit.

 

Takeda Pharmaceutical sold its DM division and OTC division to Celltrion, a South Korean company, last year.

 

The company's Actos is a representative TZD-based drug that survived the Avandia crisis, and Whituben and Albothyl are brand OTCs that everyone knows.

 

Takeda Pharmaceutical has prepared in advance for this change.

 

Takeda conducted four mergers and acquisitions, including Millenium Pharmaceutical in 2008, Nycomed in 2012, ARIAD Pharmaceuticals in 2017, and Shire in 2018.

 

Through this process, it has been strengthening major pipelines in areas such as anticancer drugs, rare diseases, and gastrointestinal diseases.

 

It quickly responded to rapidly changing market conditions.

 

At the press conference, Takeda announced that she would focus on the specialty care sector in line with her global strategy, signaling a more innovative drug launch.It presented a vision for the future of pharmaceuticals.

 

Kim Jung-hun, the first speaker, introduced the "3P (Patient, People, Product)" strategy under the title "Oncology Division's 3P Strategy for Domestic Cancer Patients." The oncology division introduced solid cancer treatments Alunbrig(Brigatinib) and Zejula(Niraparib) as notable products, saying they are generating various results by prioritizing patients first.

 

Under the theme of "Focus on Inflammatory Bowel Diseases and Fire Extinguisher Division," Kim Tae-hoon then introduced the major portfolios of the division, Kynteles(Vedolizumab) and Mezavant (Mesalazine), and he expressed his ambition to continue activities to raise awareness of the disease in the domestic market, where competition is intensifying, and to become a company specializing in treating inflammatory bowel diseases.

 

Under the title of "Korea's Rare Genetic Disease Treatment Partnership, Genetic Disease Division," Ji Chang-deok introduced Fabri's disease treatment drugs "Replagal (Agalsidase Alfa)" and Gaucher's disease treatment "Vpriv (Velaglucerase Alfa)" to improve treatment environment in Korea.

 

Finally, General Manager Kim Na-kyung introduced hemophilia treatments such as Adavate(Blood Coagulation Factor Ⅷ) & Adynovate(Rurioctocog Alfa Pegol) under the theme of "Pioneer in improving the domestic hemophilia treatment environment, Hemophilia treatment division." Moon Hee-seok, CEO of Takeda, said, "Takeda for the past 240 years has worked on creating an environment that can change patients' lives as treatment partners around the world with a series of passionate challenges and dedication to patients.

 

The company, which marks the 10th anniversary of its launch in Korea this year, will once again move forward, preparing for another 10 years through patient-centered realization and innovative treatments." Takeda celebrated its 240th anniversary on June 11th.

 

Pharmaceuticals entered the top 10 multinational pharmaceutical companies in terms of total sales in 2019 and has become a leading global bio pharmaceutical company through intensive strategies and value-based research and development for specialty care.